DTx Pharma, Inc. Sustainability Profile
DTx Pharma, Inc., a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of developing innovative therapies for patients with serious diseases. Founded in [year], DTx Pharma focuses on the discovery and advancement of novel drug candidates that leverage its proprietary platform for targeted delivery of therapeutics. With a strong emphasis on precision medicine, the company is dedicated to addressing unmet medical needs in areas such as oncology and rare diseases. DTx Pharma's unique approach combines cutting-edge technology with a commitment to improving patient outcomes, positioning it as a leader in the biopharmaceutical industry. Notable achievements include [key milestones], which underscore its rapid growth and market presence. As DTx Pharma continues to expand its operational reach, it remains committed to transforming the landscape of drug development.
DitchCarbon Score
How does DTx Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
DTx Pharma, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
DTx Pharma, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with Novartis AG, which provides a framework for its climate commitments and initiatives. As a current subsidiary of Novartis AG, DTx Pharma inherits various sustainability initiatives and targets from its parent company. Novartis has established science-based targets (SBTi) aimed at reducing greenhouse gas emissions across its operations. These initiatives include commitments to the Carbon Disclosure Project (CDP), the RE100 renewable energy initiative, and the Race to Zero campaign, all of which are cascaded to DTx Pharma. While specific reduction targets for DTx Pharma are not detailed, the overarching goals set by Novartis reflect a commitment to sustainability and climate action. This includes a focus on reducing emissions across all scopes, although specific scope data for DTx Pharma is not available. In summary, while DTx Pharma, Inc. does not currently report its own emissions data, it aligns with the climate commitments and reduction initiatives of Novartis AG, which are designed to drive significant progress in reducing carbon emissions and promoting sustainability within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is DTx Pharma, Inc.'s Industry?
How Carbon Intensive is DTx Pharma, Inc.'s Location?
DTx Pharma, Inc.'s Scope 3 Categories Breakdown
DTx Pharma, Inc.'s Scope 3 emissions, which decreased by 5% last year and increased significantly since 2013, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 78% of Scope 3 emissions.
Top Scope 3 Categories
DTx Pharma, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
DTx Pharma, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
